Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Blinded, Placebo-Controlled, Poliovirus Challenge Study To Evaluate The Therapeutic Efficacy, Safety, Tolerability And Pharmacokinetics Of Orally Administered V-073 In Healthy Adult Volunteers Receiving Type 1 Monovalent Oral Poliovirus Vaccine (mOPV1).

Next Previous
Trial Profile

A Randomized, Blinded, Placebo-Controlled, Poliovirus Challenge Study To Evaluate The Therapeutic Efficacy, Safety, Tolerability And Pharmacokinetics Of Orally Administered V-073 In Healthy Adult Volunteers Receiving Type 1 Monovalent Oral Poliovirus Vaccine (mOPV1).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs V 073 (Primary) ; Poliovirus vaccine live oral
  • Indications Poliomyelitis
  • Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors ViroDefense

    • Most Recent Events

    • 08 Dec 2016 Primary endpoint of time from initiation of treatment to virus excretion negativity as measured by virus culture of stool sample has been met, according to results published in the Journal of Infectious Diseases.
    • 08 Dec 2016 Results published in the Journal of Infectious Diseases
    • 08 Sep 2012 Planned number of patients changed from 108 to 144.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top